Dr. Safad from Hadassah Medical Center Produces Promising Results from Namodenoson for Obesity

Dr. Safad from Hadassah Medical Center Produces Promising Results from Namodenoson for Obesity

A clinical trial recently produced data that an experimental drug called Namodenoson, developed in Israel, induces weight loss in experimental models and normalizes glucose levels. The study is being conducted by Dr. Rifaat Safad at the Hadassah Medical Center in Israel. The study’s sponsor, Can-Fite BioPharma Ltd (CANF), could be onto something big as the obesity epidemic rages. This emerging biotech is a scrappy fighter with a brilliant, energetic, and tenacious academic CEO that just may prevail. Can-Fite is appropriately named—they will fight until they are successful.

The Study

The Israeli startup sponsor recently reported on new pre-clinical studies of the experimental drug that reveal a significant reduction in weight in both high-fat diet mouse models and in diabetic-rate models. Additionally, the latest lab shows the drug normalized glucose levels in a glucose tolerance test (GTT). Based on these findings, the sponsor has filed a patent with the World Intellectual Property Organization (WIPO) for the utilization of Namodenoson as an anti-obesity drug.

The Preclinical Investigator & Site

The preclinical research has been conducted at the labs of Dr. Ri...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee